ArticleGene therapy2023

AAV-mediated delivery of actoxumab and bezlotoxumab results in serum and mucosal antibody concentrations that provide protection from C. difficile toxin challenge.

Matthew M Guilleman et al.PubMed ↗Publisher ↗

No numbers read from the abstract.